Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
Intermittent fasting linked to higher risk of cardiovascular death, research suggests
Intermittent fasting, a diet pattern that involves alternating between periods of fasting and eating, can lower blood pressure and...
-
California becomes the first state to ban four chemicals in food, including red dye No. 3
California Gov. Gavin Newsom has signed a bill that bans four food additives linked to health problems, the first...
-
Flu is hitting hard in the Southeast and the West and other states should prepare, doctors warn
As kids go back to school and families return to a post-holiday routine, flu season is on track to...
-
The second-largest ethnic group in Orange County has the lowest vaccination rate
ANAHEIM, Calif. — A Latino Covid-19 vaccination gap in California’s third largest county has medical workers and community groups scrambling...
-
CDC signs off on Pfizer Covid booster for kids 5-11
The Centers for Disease Control and Prevention on Thursday signed off on booster shots of the Pfizer-BioNTech Covid-19 vaccine...
-
Slow it down, South Korea tells gym users as Covid cases spike
Slow it down if you want to feel the burn — that’s what South Korean officials are telling gym...
-
CDC strengthens advice for boosters as omicron variant spreads globally
All adults should get Covid-19 booster shots when they’re eligible, the Centers for Disease Control and Prevention said Monday,...
-
Their babies died when Camp Lejeune’s water was poisoned. But justice has been hard to find
‘Someone dropped the ball’ In the early 1970s, Kozobarich said adverse birth outcomes were so widespread among women on...
Recent Comments